STOCKHOLM, Jan. 24, 2020 /PRNewswire/ -- Oncopeptides AB
(Nasdaq Stockholm: ONCO) announces today that it will host a
webcast at 11am (CET) on Monday,
January 27th 2020 where CEO Jakob Lindberg will present and explain
melflufen's mechanism of action.
Conference call for investors, analysts and the media,
Monday, January
27th 2020, at 11 (CET).
Phone numbers for participants from:
Sweden: +46-8-505-58-352
Europe: +44-3333-009-262
USA: +1-833-526-8347
The conference call will also be streamed on the corporate
website www.oncopeptides.com and via the link below.
https://tv.streamfabriken.com/2020-01-27-oncopeptides-press-conference
The presentation will be available at:
www.oncopeptides.com / Investor Relations / Presentations /
Presentation webcast melflufen mechanism-of-action/
For more information, please contact:
Rein Piir, Head of Investor Relations at Oncopeptides
E-mail: rein.piir@oncopeptides.com
Cell phone: +46-70-853-72-92
This information was submitted for publication at 18.30 CET
January 24, 2020.
About melflufen
Melflufen is a novel peptide-drug conjugate that rapidly
delivers a cytotoxic payload into tumor cells. Melflufen is rapidly
taken up by myeloma cells due to its high lipophilicity and is
immediately cleaved by peptidases to deliver an entrapped
hydrophilic alkylator payload. Peptidases play a key role in
protein homeostasis and feature in cellular processes such as
cell-cycle progression and programmed cell death. In vitro,
melflufen is 50-fold more potent in myeloma cells than the
alkylator payload itself due to the increased intracellular
alkylator concentration. Melflufen displays cytotoxic activity
against myeloma cell lines resistant to other treatments, including
alkylators, and has also demonstrated inhibition of DNA repair
induction and angiogenesis in preclinical studies.
About Oncopeptides
Oncopeptides is a pharmaceutical company focused on the
development of targeted therapies for difficult-to-treat
hematological diseases. The company is focusing on the development
of the lead product candidate melflufen, a novel peptide-drug
conjugate that rapidly delivers a cytotoxic payload into tumor
cells. Melflufen is in development as a new treatment for the
hematological cancer multiple myeloma and is currently being tested
in multiple clinical studies including the pivotal phase 2 HORIZON
study and the ongoing phase 3 OCEAN study. Oncopeptides'
headquarters is in Stockholm,
Sweden, and the company is listed in the Mid Cap segment on
Nasdaq Stockholm with the ticker ONCO.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/oncopeptides-ab/r/oncopeptides-will-host-a-webcast-on-monday--january-27-th--at-11-00--cet-,c3016794
The following files are available for download:
https://mb.cision.com/Main/15404/3016794/1179485.pdf
|
Press
release_WEBCAST
|
View original
content:http://www.prnewswire.com/news-releases/oncopeptides-will-host-a-webcast-on-monday-january-27th-at-11-00-cet-300992912.html
SOURCE Oncopeptides AB